32 research outputs found

    Propiedades psicométricas del Coronavirus Anxiety Scale (CAS) en adolescentes, Chiclayo 2022

    Get PDF
    El presente estudio estableció como objetivo general: determinar las propiedades psicométricas del Coronavirus Anxiety Scale (CAS) en adolescentes de la ciudad de Chiclayo. La investigación fue aplicada de tipo instrumental y con diseño psicométrico; la muestra fue seleccionada a través de un muestreo no probabilístico por conveniencia, la misma que estuvo conformada por 384 adolescentes entre hombres y mujeres pertenecientes a una institución educativa de Chiclayo. Los principales resultados demostraron que se logró evidenciar adecuadas propiedades psicométricas de la Coronavirus Anxiety Scale (CAS). Con respecto a la validez de contenido se optó por el método juicio de expertos y el coeficiente V de Aiken el cual arrojó valores aceptables (>0.90). Además, se evidenció que los 5 ítems mostraron adecuados índices de asimetría y curtosis (+/-1.5); además adecuados índices de homogeneidad (>30); y cargas factoriales (>0.30). En lo que concierne a la validez de constructo, se demostró que el instrumento unidimensional compuesto por 5 reactivos presenta adecuados índices de bondad de ajuste. Por último, a través del coeficiente Alpha y Omega, se obtuvo un valor de 0,86, lo que demuestra una excelente confiabilidad del Coronavirus Anxiety Scale (CAS)

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three

    No full text

    Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

    No full text
    10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

    Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

    No full text

    Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial

    No full text

    Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

    No full text

    Alirocumab reduces total hospitalizations and increases days alive and out of hospital in the ODYSSEY OUTCOMES trial

    No full text
    corecore